Biopharma supply chain: Balancing pressing priorities

Scroll Down

With intense pressure continuing to be placed upon the pharmaceutical industry to rapidly develop and produce vaccines and therapies to address the COVID-19 pandemic, it is imperative that biopharma supply chains adapt their practices to ensure they are robust enough to simultaneously deal with their existing workload.

In this article, Bill Vincent, chairman and CEO at Genezen, provides insight into why there is now an accelerated demand for product as a result of the COVID-19 pandemic and outlines how CDMOs are dealing with this pressure despite constraints on the supply of raw materials as well as manufacturing capacity issues.

Read the full article here: Balancing Pressing Priorities

You may also be interested in...

Genezen completes cGMP-lentiviral and retroviral vector…

Genezen, a cell and gene therapy Contract Development and Manufacturing Organization...

Read more

Genezen announces launch of Scientific Advisory…

Leading experts in cell and gene therapy will provide guidance to...

Read more

Overcoming development and manufacturing challenges with…

As efficient and effective tools for gene transduction and delivering genes...

Read more

Retroviruses in CAR-T therapies: From gamma…

Introduction In recent years, chimeric antigen receptor T (CAR-T) cells have...

Read more